Review of the REPRISE Trial: Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Journal Title: Nephrology – Open Journal - Year 2018, Vol 4, Issue 1
Abstract
In the past, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and its Outcomes (TEMPO) trial showed Tolvaptan, a vasopressin V2-receptor antagonist, slowed the decline in the estimated Glomerular Filtration Rate (eGFR) in patients with estimated creatinine clearance of ≥60 ml per minute. With this in consideration, Replicating Evidence of Preserved Renal Function: Investigation of Tolvaptan Safety and Efficacy (REPRISE) trial was conducted to assess the efficacy and safety of Tolvaptan in patients with later stage ADPKD. In this trial, 1370 patients with later-stage ADPKD were randomized. These patients were either 18 to 55-years-old with eGFR of 25 to 65 mL per minute per 1.73 m2 of body surface area or 56 to 65-years-old with eGFR of 25 to 44 mL per minute per 1.73 m2 . The primary end-point of this trial was the change in eGFR between baseline and end of trial period, with adjustments made for exact duration that each patient participated for, interpolated to 1 year. The change from baseline that was noted in the Tolvaptan group was -2.34 mL per minute per 1.73 m2 vs. -3.61 mL per minute per 1.73 m2 in the placebo group. A difference of 1.27 mL per minute per 1.73 m2 (95% CI, p less than 0.001) was noted. Based on the data collected by the REPRISE trial over a 1-year period, it can be concluded that Tolvaptan slows the decline in eGFR than placebo in patients with later stage ADPKD.
Authors and Affiliations
Soroush Nomigolzar, Himax Patel
Keywords
Related Articles
- EP ID EP558760
- DOI 10.17140/NPOJ-4-119
- Views 162
- Downloads 0
A New Hypothesis: The Immunomodulatory Effects of Mesenchymal Stromal Cell Derived Extracellular Vesicles in Ischemic Kidney Injury Partly through Spleen
Ischemic Reperfusion Injury (IRI) is a major reason for Acute Kidney Injury (AKI) in hospitalization patients and could continue to result in end-stage kidney fibrosis. Mesenchymal Stromal Cells (MSCs) are regarded as a...
Individualized Sodium Prescription in Hemodialysis: An Ally for Better Dialysis Outcomes?
The current practice in dialysis centres all over the world is to use standard sodium dialysate for all patients. Recently, there is a lot of interest in manipulating the dialysate sodium concentration to reduce fluid ov...
Hypertension-Chronic Kidney Disease Relationships
A large number of epidemiologic, clinical and experimental studies indicate a strong association between hypertension (HT) and chronic kidney disease (CKD).1 Further, this association portends an ominous prognosis. Patie...
Comparison of Hospital-Acquired and Community-Acquired Acute Kidney Injury in Hospitalized Patients
Introduction: Little is known about patients sustaining Acute Kidney Injury (AKI) in the Community Acquired Acute Kidney Injury (CA-AKI) and how this differs from AKI in Hospital Acquired Acute Kidney Injury (HA-AKI). Th...
Individualized Sodium Prescription inHemodialysis: An Ally for Better DialysisOutcomes?
The current practice in dialysis centres all over the world is to use standard sodium dialysate for all patients. Recently, there is a lot of interest in manipulating the dialysate sodium concentration to reduce fluid ov...